Stoke Therapeutics, Inc. (STOK) Investor Relations Documents

Stoke Therapeutics, Inc. (STOK) investor relations documents from the company's IR site: 17 press releases. Read in-app with summaries. First-party data.

Investor relations documents — source: company IR site

Published	Type	Document
2026-08-18	Press release	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2026-08-05	Press release	Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference
2026-08-03	Press release	Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates
2026-07-27	Press release	Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Updates
2026-07-16	Press release	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2026-07-13	Press release	Stoke Therapeutics Appoints Thomas McCauley, Ph.D., as Chief Scientific Officer
2026-06-30	Press release	Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an
2026-06-16	Press release	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2026-05-28	Press release	Stoke Therapeutics to Present at Upcoming Investor Conferences in June
2026-05-18	Press release	Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2026-05-07	Press release	Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates
	Press release	Read More
	Press release	Read More
	Press release	Read More
	Press release	Read More
	Press release	Read More
	Press release	Read More

STOK overview · STOK earnings · STOK financials · STOK KPIs · STOK documents · STOK ownership · STOK peers

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.